SG11201811515WA - Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide - Google Patents
Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamideInfo
- Publication number
- SG11201811515WA SG11201811515WA SG11201811515WA SG11201811515WA SG11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA SG 11201811515W A SG11201811515W A SG 11201811515WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- london
- methylbenzamide
- amino
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 011111111111111111001111111011111111111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/011579 Al 18 January 2018 (18.01.2018) W I P0 I P C T (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 31/415 (2006.01) A61P 29/00 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7D 231/38 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/GB2017/052056 Published: — with international search report (Art. 21(3)) (22) International Filing Date: 13 July 2017 (13.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1612240.0 14 July 2016 (14.07.2016) GB (71) Applicant: MEREO BIOPHARMA 1 LIMITED [ /GB]; 1 Cavendish Place, London, Greater London W1G OQF (GB). (72) Inventors: SULEIMAN, Osama; Johnson Matthey Plc., Fine Chemicals Division (Pharmorphix), 250 Cambridge _ Science Park, Milton Road, Cambridge Cambridgeshire CB4 OWE (GB). PEREZ, Lucia Romero; Johnson — Matthey Plc., Johnson Matthey Chemical Product, Or- = - chard Road, Royston, Hertfordshire SG8 5HE (GB). HAR- _ LACHER, Cornelius Stephan; Zihlackerstrasse 60, 4153 =_ Reinach (CH). JONES, Stewart; Mereo Biopharma Group plc, 4th Floor, 1 Cavendish Place, London, Greater London = W1G OQF (GB). Agent: GILL JENNINGS & EVERY LLP et al.; The (74) Broadgate Tower, 20 Primrose Street, London, Greater Lon- don EC2A 2ES (GB). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — 1-1 01 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, IN 1 1 in ,—, ,-1 (54) Title: METHOD FOR PRODUCING A POLYMORPHIC FORM OF 3-[5-AMINO-4-(3- CYANOBENZOYL)-PYRA- 0 ZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE --.... , 1 (57) : This invention relates to a process for the preparation of Form A of 3-[5-amino-4-(3- cyanobenzoy1)-pyrazol-1-y1]-N- 0 cyclopropyl-4-methylbenzamide. Also disclosed herein is Form A of 345-amino-4-(3-cyanobenzoy1)-pyrazol-1-y1]-N-cyclopropy1-4- el methylbenzamide, or pharmaceutical compositions thereof, obtainable by the process described herein. C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612240.0A GB201612240D0 (en) | 2016-07-14 | 2016-07-14 | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
| PCT/GB2017/052056 WO2018011579A1 (en) | 2016-07-14 | 2017-07-13 | Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811515WA true SG11201811515WA (en) | 2019-01-30 |
Family
ID=56890600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811515WA SG11201811515WA (en) | 2016-07-14 | 2017-07-13 | Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10934260B2 (en) |
| EP (1) | EP3484471B1 (en) |
| JP (1) | JP7094021B2 (en) |
| KR (1) | KR102460529B1 (en) |
| CN (1) | CN109414429B (en) |
| AU (1) | AU2017294643B2 (en) |
| BR (1) | BR112019000460A2 (en) |
| CA (1) | CA3030622A1 (en) |
| DK (1) | DK3484471T3 (en) |
| ES (1) | ES2874661T3 (en) |
| GB (1) | GB201612240D0 (en) |
| HU (1) | HUE054539T2 (en) |
| IL (1) | IL263908B (en) |
| MX (1) | MX2019000385A (en) |
| PL (1) | PL3484471T3 (en) |
| PT (1) | PT3484471T (en) |
| SG (1) | SG11201811515WA (en) |
| WO (1) | WO2018011579A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1075467B1 (en) | 1998-05-05 | 2005-03-30 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as p-38 map kinase inhibitors |
| SI2298743T1 (en) | 2003-06-26 | 2012-12-31 | Novartis Ag | 5-membered heterocycle-based P38 kinase inhibitors |
| WO2013139809A1 (en) | 2012-03-20 | 2013-09-26 | Novartis Ag | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
| MX2018010781A (en) | 2016-03-08 | 2018-11-09 | Mereo Biopharma 1 Ltd | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions. |
| BR112018067454A2 (en) | 2016-03-08 | 2019-01-15 | Mereo Biopharma 1 Ltd | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
| GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
-
2016
- 2016-07-14 GB GBGB1612240.0A patent/GB201612240D0/en not_active Ceased
-
2017
- 2017-07-13 MX MX2019000385A patent/MX2019000385A/en unknown
- 2017-07-13 DK DK17742278.9T patent/DK3484471T3/en active
- 2017-07-13 US US16/317,012 patent/US10934260B2/en active Active
- 2017-07-13 HU HUE17742278A patent/HUE054539T2/en unknown
- 2017-07-13 KR KR1020197001012A patent/KR102460529B1/en active IP Right Grant
- 2017-07-13 BR BR112019000460-2A patent/BR112019000460A2/en unknown
- 2017-07-13 CA CA3030622A patent/CA3030622A1/en active Pending
- 2017-07-13 CN CN201780041222.XA patent/CN109414429B/en active Active
- 2017-07-13 IL IL263908A patent/IL263908B/en unknown
- 2017-07-13 PT PT177422789T patent/PT3484471T/en unknown
- 2017-07-13 PL PL17742278T patent/PL3484471T3/en unknown
- 2017-07-13 SG SG11201811515WA patent/SG11201811515WA/en unknown
- 2017-07-13 AU AU2017294643A patent/AU2017294643B2/en active Active
- 2017-07-13 ES ES17742278T patent/ES2874661T3/en active Active
- 2017-07-13 EP EP17742278.9A patent/EP3484471B1/en active Active
- 2017-07-13 WO PCT/GB2017/052056 patent/WO2018011579A1/en unknown
- 2017-07-13 JP JP2019501463A patent/JP7094021B2/en active Active
-
2021
- 2021-01-14 US US17/149,649 patent/US11434204B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3484471T (en) | 2021-06-02 |
| WO2018011579A1 (en) | 2018-01-18 |
| RU2019103880A (en) | 2020-08-14 |
| US20210206726A1 (en) | 2021-07-08 |
| JP2019520420A (en) | 2019-07-18 |
| EP3484471A1 (en) | 2019-05-22 |
| JP7094021B2 (en) | 2022-07-01 |
| US10934260B2 (en) | 2021-03-02 |
| PL3484471T3 (en) | 2021-09-20 |
| CA3030622A1 (en) | 2018-01-18 |
| AU2017294643A1 (en) | 2019-01-17 |
| EP3484471B1 (en) | 2021-05-05 |
| MX2019000385A (en) | 2019-05-23 |
| HUE054539T2 (en) | 2021-09-28 |
| CN109414429B (en) | 2021-09-14 |
| RU2019103880A3 (en) | 2020-09-29 |
| IL263908B (en) | 2022-07-01 |
| US11434204B2 (en) | 2022-09-06 |
| US20190352269A1 (en) | 2019-11-21 |
| KR102460529B1 (en) | 2022-10-31 |
| AU2017294643B2 (en) | 2021-02-25 |
| ES2874661T3 (en) | 2021-11-05 |
| BR112019000460A2 (en) | 2019-04-24 |
| KR20190028432A (en) | 2019-03-18 |
| CN109414429A (en) | 2019-03-01 |
| DK3484471T3 (en) | 2021-05-31 |
| IL263908A (en) | 2019-01-31 |
| GB201612240D0 (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201803900UA (en) | Process for preparing polyurea microcapsules with improved deposition | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201804398XA (en) | Method for producing rna molecule compositions | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201809630RA (en) | Nicotine particles |